421 related articles for article (PubMed ID: 18206436)
1. Recent advances in the hormonal treatment of breast cancer.
Boughey JC; Buzdar AU; Hunt KK
Curr Probl Surg; 2008 Jan; 45(1):13-55. PubMed ID: 18206436
[No Abstract] [Full Text] [Related]
2. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
3. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Dang C; Hudis C
Clin Breast Cancer; 2006 Apr; 7(1):51-8. PubMed ID: 16764744
[TBL] [Abstract][Full Text] [Related]
4. [Therapy studies of the Austrian Breast Cancer Group (ABC)].
Jakesz R; Hausmaninger H; Samonigg H; Kubista E; Haider K; Mlineritsch B; Schmid M; Tausch C; Reiner G; Renner K; Stierer M; Jatzko G; Hofbauer F; Fridrik M; Schennach W; Sevelda P; Dadak C; Haid A; Scholz R; Lenzhofer P; Steindorfer P; Berger A; Mischinger HJ
Zentralbl Chir; 1998; 123 Suppl 5():28-32. PubMed ID: 10063568
[TBL] [Abstract][Full Text] [Related]
5. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
Hayward RL; Dixon JM
Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Hudis C
Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant clodronate in breast cancer.
Paterson AH
Acta Oncol; 2005; 44(1):80-2; author reply 83-4. PubMed ID: 15848910
[No Abstract] [Full Text] [Related]
9. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.
Schott A; Hayes DF
J Clin Oncol; 2004 Dec; 22(23):4660-2. PubMed ID: 15505274
[No Abstract] [Full Text] [Related]
11. Adjuvant therapy for node-negative breast cancer: a proactive view.
Glick JH
Important Adv Oncol; 1990; ():183-97. PubMed ID: 2182518
[No Abstract] [Full Text] [Related]
12. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
13. Systemic (adjuvant) treatment of primary breast cancer.
Somani N
J Assoc Physicians India; 2001 Apr; 49():451-3. PubMed ID: 11762618
[TBL] [Abstract][Full Text] [Related]
14. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Dickler M
Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
[No Abstract] [Full Text] [Related]
15. Breast cancer: metastatic.
Johnston S; Stebbing J
Clin Evid; 2002 Jun; (7):1579-602. PubMed ID: 12230774
[No Abstract] [Full Text] [Related]
16. Dose density in breast cancer: a simple message?
Lin NU; Gelman R; Winer EP
J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
[No Abstract] [Full Text] [Related]
17. Concurrent versus sequential radiotherapy and tamoxifen in breast cancer - The CONSET trial is launched.
Munshi A; Gupta D
Acta Oncol; 2011 Jan; 50(1):154-5. PubMed ID: 20843175
[No Abstract] [Full Text] [Related]
18. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
Wolff AC; Davidson NE
J Clin Oncol; 2006 Nov; 24(31):4949-51. PubMed ID: 17075110
[No Abstract] [Full Text] [Related]
19. Novel systemic therapies for breast cancer.
Lo S; Johnston SR
Surg Oncol; 2003 Dec; 12(4):277-87. PubMed ID: 14998568
[TBL] [Abstract][Full Text] [Related]
20. To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?
Wang PH; Chao HT
Taiwan J Obstet Gynecol; 2008 Sep; 47(3):372-4. PubMed ID: 18936014
[No Abstract] [Full Text] [Related]
[Next] [New Search]